Top Page
Compumedics Limited
(Sydney:CMP)
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
Compumedics Limited Business Overview & Revenue Model
Compumedics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.04M | 51.04M | 49.72M | 42.41M | 37.76M | 35.74M |
| Gross Profit | 30.99M | 30.99M | 26.07M | 21.59M | 19.32M | 19.16M |
| EBITDA | 1.94M | 1.94M | 2.79M | -5.05M | 3.31M | 2.56M |
| Net Income | -1.27M | -1.27M | -338.00K | -6.12M | 1.36M | 998.00K |
Balance Sheet | ||||||
| Total Assets | 54.39M | 54.39M | 40.36M | 41.18M | 41.71M | 38.55M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.69M | 1.89M | 3.80M | 7.29M | 6.77M |
| Total Debt | 13.88M | 13.88M | 8.58M | 9.47M | 6.55M | 5.82M |
| Total Liabilities | 32.57M | 32.57M | 22.15M | 22.89M | 18.12M | 16.39M |
| Stockholders Equity | 21.82M | 21.82M | 18.21M | 18.29M | 23.59M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | 467.00K | 467.00K | -986.00K | -4.36M | 302.00K | -230.00K |
| Operating Cash Flow | 681.00K | 681.00K | 2.00M | 49.00K | 3.29M | 1.32M |
| Investing Cash Flow | -7.35M | -7.37M | -2.99M | -4.41M | -2.98M | -1.55M |
| Financing Cash Flow | 6.10M | 6.10M | -1.49M | -1.00M | 1.61M | -179.00K |
Compumedics Limited Technical Analysis
Compumedics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$174.55M | -50.00 | -7.26% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$27.44M | -2.92 | -103.74% | ― | 14.84% | 39.64% | |
50 Neutral | AU$105.58M | -7.86 | -31.98% | ― | 34.20% | -23.90% | |
50 Neutral | AU$76.91M | -55.80 | -6.35% | ― | 2.23% | -263.16% | |
48 Neutral | AU$71.31M | -3.04 | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$165.43M | -15.52 | -70.55% | ― | ― | -257.32% |
Compumedics Limited Corporate Events
Compumedics Limited has secured a new $4.9 million MEG sales order from Beijing Normal University, bringing its total MEG sales to $25 million. This order strengthens Compumedics’ leadership in the Chinese neuro-imaging market and supports its growth strategy, with plans for further expansion in China, North America, and Europe. The deal highlights the company’s innovative MEG products and positions it for sustainable revenue growth through FY27.
Compumedics Limited has announced the issuance of 7,543,860 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, reflecting the company’s ongoing efforts to strengthen its market position and enhance its financial flexibility. The issuance of these securities is expected to support Compumedics’ strategic initiatives and potentially impact its operational capabilities and stakeholder interests.
Compumedics Limited held its Annual General Meeting on October 30, 2025, where key resolutions were voted on by shareholders. The election of Mr. Christopher Barys as a director and the adoption of the remuneration report were both carried with significant support. These outcomes reflect shareholder confidence in the company’s leadership and strategic direction, potentially strengthening its market position and stakeholder relations.
Compumedics Limited has issued 7,543,860 fully paid ordinary shares to Australian institutional investors at AU$0.285 per share. This issuance, which did not require disclosure under the Corporations Act, aligns with Compumedics’ compliance with relevant legislative provisions. The move is part of the company’s ongoing efforts to strengthen its financial position and expand its market reach.
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a projected revenue of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neurological diagnostics across various regions, including Australia, Japan, China, and the USA, and continues to expand its presence in the global medical technology market.
Compumedics Limited has secured early FDA approval for its Somfit D product and raised $2.15 million to accelerate its commercialization in the US home sleep testing market. The company is entering a significant commercial expansion phase, with strategic growth pillars including scaling Somfit in the US, expanding OrionMEG globally, and leveraging SaaS-driven margin expansion. The funds will be used to fast-track production and support the growing demand for Somfit D and OrionMEG, positioning Compumedics for a structural valuation re-rating against peers.
Compumedics Limited has requested a trading halt on the Australian Securities Exchange, effective immediately, pending an announcement regarding a proposed capital raising. The halt is expected to last until the start of normal trading on October 15, 2025, unless an announcement is made earlier. This move indicates that Compumedics is preparing for a significant financial development, which could impact its market position and stakeholder interests.
Compumedics Limited reported record sales orders of $63.4 million, marking a 22% increase, and revenue of $51 million, up 15% from the previous year. The company has achieved significant growth in its Somfit SaaS platform, securing a $10 million U.S. pipeline and forming strategic partnerships with major pharmaceutical companies. With FDA clearance for its products and expansion into new markets, Compumedics is positioned for continued growth in FY26, projecting revenues over $70 million.
Compumedics Limited has reaffirmed its commitment to high standards of corporate governance, emphasizing the importance of a strong relationship between the Board and senior management for the Group’s long-term success. The Board’s responsibilities include strategic guidance, financial oversight, and ensuring effective management processes, with a focus on enhancing shareholder and stakeholder interests.
Compumedics Limited has announced details regarding its upcoming Annual General Meeting, which will be held virtually and physically on October 30, 2025. Shareholders are encouraged to participate through an online platform, where they can watch, listen, and vote on various resolutions, including the election of a director and the adoption of a remuneration report. This meeting is significant for stakeholders as it provides an opportunity to influence key decisions and company governance.
Compumedics Limited has announced its Annual General Meeting (AGM) scheduled for October 30, 2025, which will be held as a hybrid event, allowing shareholders to participate both in-person and virtually via a Zoom webinar. The AGM will cover the company’s financial statements, the election of a director, and the adoption of the remuneration report. The meeting provides an opportunity for shareholders to engage with the company’s leadership and vote on key resolutions, reflecting Compumedics’ commitment to transparency and shareholder involvement.
Compumedics Limited has released its 2025 Annual Report, highlighting its strategic growth platforms and core products in the sleep and neuroscience sectors. The report outlines the company’s ongoing commitment to innovation and market expansion, which is expected to enhance its industry positioning and provide significant value to stakeholders.
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a forecast of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neuro diagnostics in Australia and Japan, is the top supplier of sleep diagnostics devices in China, and ranks as the third supplier of TCD devices in Germany and neurological monitoring devices in the USA, enhancing its industry positioning and stakeholder confidence.
Compumedics Limited has appointed Christopher R. Barys, a seasoned MedTech executive, as a Non-Executive Director to enhance its U.S. growth and capital market strategy. This strategic move aims to leverage Barys’ extensive experience and networks to address the company’s valuation gap compared to global peers and accelerate the commercialization of its Somfit® and OrionMEG® products. The company reported a 22% year-on-year increase in sales orders and anticipates further growth with a projected revenue exceeding $70 million in FY26. The strengthened board will focus on strategic partnerships and investor relations to unlock Compumedics’ potential in the U.S. market.